Added
Updated
Gamgee produces a personalized mRNA cancer vaccine for dogs, built individually for each patient rather than manufactured as a fixed formula. A treating veterinarian submits a tumour sample and a matched healthy sample; the company sequences both, identifies the mutations present only in the cancer, and ranks which of them the immune system can best be taught to attack.
The selected targets are encoded into a patient-specific mRNA construct that is manufactured and delivered to the clinic with a dosing schedule, and outcomes are monitored afterwards. Gamgee delivers this through an investigational clinical trial in Australia and through a referral and case-management service for veterinary clinics.
Canine cancer is a leading cause of death in older dogs, and existing options are largely surgery, chemotherapy, and radiotherapy that are applied to the tumour type rather than to the individual animal. Personalized mRNA therapeutics sit at the intersection of two trends: falling sequencing costs that make per-patient genomic analysis viable, and the mRNA manufacturing capacity built out during the COVID-19 pandemic.
Regulatory treatment of patient-specific veterinary biologics is still forming. Gamgee has referenced the United States Department of Agriculture pathway for patient-specific veterinary biologics as the route for its product outside a trial setting, while conducting early human-relevant work through academic collaborators in Australia.
Gamgee runs an end-to-end pipeline rather than a single step of it, covering intake, tissue collection, genomic analysis, vaccine design, manufacturing coordination, treatment support, and response monitoring. This lets a referring clinic hand over a case and receive a finished, patient-specific product instead of assembling a chain of separate genomics and manufacturing vendors.
A second advantage is the canine-specific focus of its neoantigen selection: models and target ranking are trained on canine tumour biology rather than adapted from human oncology, and the company works directly with Australian academic genomics and RNA research groups. Its clinical trial also generates proprietary canine oncology data that compounds as more cases are processed.
